Author: Business Wire

Jacobs Engineering Selected by Aerie Pharmaceuticals as its Engineering Contractor for Aerie’s First Pharmaceutical Manufacturing Facility

DALLAS–(BUSINESS WIRE)–Jacobs Engineering Group Inc. (NYSE:JEC) has been selected by Aerie Pharmaceuticals Inc. (NASDAQ:AERI) to provide engineering, procurement and construction management services (EPCM) for Aerie’s first pharmaceutical manufacturing facility, located in the Industrial Development Authority (IDA)’s advanced technology building in Athlone, Republic of Ireland. Under the terms of the contract, Jacobs will outfit Aerie’s manufacturing facility for commercial processing of ster

Aerie Pharmaceuticals Announces Appointment of Tori Arens as Vice President of Drug Product Manufacturing and Eric Carlson, Ph.D. as Vice President of Research and Development

IRVINE, Calif.–(BUSINESS WIRE)–Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of open-angle glaucoma and other diseases of the eye, today announced the appointment of Tori Arens as Vice President of Drug Product Manufacturing, reporting to Kenneth Ruettimann, Ph.D., Aerie’s Vice President of Manufacturing. Aerie also announced the appointment of Eric Ca

GenSight Biologics intègre les indices CAC® Small, CAC® Mid and Small et CAC® All-Tradable d’Euronext

PARIS–(BUSINESS WIRE)–Regulatory News: GenSight Biologics (Paris:SIGHT) (Euronext : SIGHT, ISIN : FR0013183985, éligible PEA-PME), société biopharmaceutique dédiée à la découverte et au développement de thérapies géniques innovantes pour le traitement des maladies neurodégénératives de la rétine et du système nerveux central, annonce avoir intégré, à compter du 18 septembre 2017, les indices CAC® Small, CAC® Mid and Small et CAC® All-Tradable suite à leur révision annuelle par le Conseil Scie

GenSight Biologics Integrates the CAC® Small, CAC® Mid and Small and CAC® All-Tradable Euronext Indexes

PARIS–(BUSINESS WIRE)–Regulatory News: GenSight Biologics (Paris:SIGHT) (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company that discovers and develops innovative gene therapies for neurodegenerative retinal diseases and diseases of the central nervous system, announced its stock has been included, as of September 18, 2017, in the CAC® Small, CAC® Mid and Small and CAC® All-Tradable indexes following their annual review by the Euronext Scientific Board on Indices. Tho

BioTime Awarded Grant from the NIH

ALAMEDA, Calif.–(BUSINESS WIRE)–BioTime, Inc. (NYSE American:BTX), a clinical-stage biotechnology company focused on developing and commercializing products addressing degenerative diseases, today announced that it has been awarded a grant of up to $1.56 million from the Small Business Innovation Research program of the National Institutes of Health (NIH). The grant provides funding to further develop BioTime’s innovative, next generation vision restoration program for more advanced retinal d

Deux nouvelles lentilles intraoculaires EDOF innovantes de fabrication suisse pour l’opération de la cataracte

NEUCHÂTEL, Suisse–(BUSINESS WIRE)–La société Swiss Advanced Vision (SAV-IOL SA) a annoncé aujourd’hui le lancement de LUCIDIS et EDEN, deux nouvelles lentilles intraoculaires (LIO) pour la chirurgie de la cataracte, toutes deux équipées de la technologie brevetée EDOF Instant Focus. Avec un tout nouveau concept, LUCIDIS apporte deux progrès majeurs au marché monofocal : elle prolonge la profondeur de focalisation d’une lentille monofocale, tout en étant la première LIO EDOF abordable. Grâce à

Fabrican en Suiza dos nuevas e innovadores lentes intraoculares con profundidad de foco extendida para cirugía de cataratas

NEUCHATEL, Suiza–(BUSINESS WIRE)–La compañía Swiss Advanced Vision (SAV-IOL SA) anunció hoy el lanzamiento de LUCIDIS y EDEN, dos nuevas lentes intraoculares (LIO) para la cirugía de cataratas, con la tecnología patentada de profundidad de foco extendida (Extended Depth of Focus, EDOF) Instant Focus. Con un concepto totalmente nuevo, LUCIDIS aporta dos importantes logros para el mercado monofocal: extender la profundidad de foco en lentes monofocales y ser el primer LIO con EDOF económico. Gr

Zwei neue innovative Swiss Made EDOF IOLs für die Kataraktchirurgie

NEUCHATEL, Schweiz–(BUSINESS WIRE)–Das Unternehmen Swiss Advanced Vision (SAV-IOL SA) meldete heute die Einführung von LUCIDIS und EDEN. Dabei handelt es sich um zwei neue Intraokularlinsen (IOLs) für die Kataraktchirurgie, die beide auf der patentierten Technologie EDOF Instant Focus basieren. Mit einem brandneuen Konzept bereichert LUCIDIS den monofokalen Markt durch zwei wesentliche Errungenschaften: zum einen verfügt die monofokale Linse über eine erweiterte Tiefenschärfe, zum anderen ist

Riassunto: Due nuove lenti intraoculari EDOF prodotte in Svizzera per la chirurgia della cataratta

NEUCHATEL, Svizzera–(BUSINESS WIRE)–Swiss Advanced Vision (SAV-IOL SA) ha oggi annunciato il lancio di LUCIDIS ed EDEN, due nuove lenti intraoculari (IOL) per la chirurgia della cataratta, entrambe basate sulla tecnologia EDOF brevettata Instant Focus. Basata su un concetto assolutamente innovativo, la lente LUCIDIS offre due importanti vantaggi per il mercato monofocale: estende la profondità di fuoco delle lenti monofocali ed è anche la prima IOL EDOF conveniente. Grazie all’avanzato design

Duas Novas Lentes Intraoculares Inovadoras EDOF Produzidas nas Suíça para Cirurgia de Catarata

NEUCHATEL, Suíça–(BUSINESS WIRE)–A empresa Swiss Advanced Vision (SAV-IOL SA) anunciou hoje o lançamento das LUCIDIS e EDEN, duas novas lentes intraoculares (IOLs) para cirurgia de catarata, ambas utilizando a tecnologia patenteada Instant Focus EDOF. Com um novo conceito de marca, a LUCIDIS traz duas importantes conquistas para o mercado monofocal: ampliar a profundidade do foco em uma lente monofocal enquanto se torna a primeira lente intraocular EDOF acessível. Graças ao seu perfil refrati

瑞士生產出兩款用於白內障手術的創新EDOF人工水晶體

瑞士納沙泰爾–(BUSINESS WIRE)–(美國商業資訊) — Swiss Advanced Vision公司(SAV-IOL SA)今天宣布上市兩種用於白內障手術的新款人工水晶體(IOL) LUCIDIS和EDEN,均採用Instant Focus EDOF專利技術。LUCIDIS採用全新概念,為單焦點市場帶來兩項重大成就:延伸單焦點水晶體的焦點深度,同時是首款平價EDOF人工水晶體。受惠於其先進的折射設計,它可實現向近距離和中距離視力的延伸。同時,SAV-IOL立足於InFo水晶體的成功,正憑藉便捷的氣泡包裝EDEN為多焦點市場建立精品混合區隔市場的參照物,提供高性能的連續視力。 Swiss Advanced Vision執行長Max Boysset表示:「透過EDEN,我們從高視力性能方面鞏固了現有的產品陣容,依據是我們收到患者熱烈的回饋。而LUCIDIS的定位完全不同:它是突破性產品,向患者提供平價的延伸視力。LUCIDIS能夠作為首款EDOF單焦點水晶體上市,我們感到很興奮。我們的使命是向最多人數的患者提供瑞士生產的EDOF技術。SAV-IOL現在憑藉LUCIDI

瑞士生产出两款用于白内障手术的创新EDOF人工晶体

瑞士纳沙泰尔–(BUSINESS WIRE)–(美国商业资讯) — Swiss Advanced Vision公司(SAV-IOL SA)今天宣布上市两种用于白内障手术的新款人工晶体(IOLs) LUCIDIS和EDEN,均采用Instant Focus EDOF专利技术。LUCIDIS采用全新概念,为单焦点市场带来两项重大成就:延伸单焦点晶状体的焦点深度,同时是首款平价EDOF人工晶体。得益于其先进的折射设计,它可实现向近距和中距视力的延伸。同时,SAV-IOL立足于InFo晶状体的成功,正凭借便捷的气泡包装EDEN为多焦点市场创建精品混合细分市场的参照物,提供高性能的连续视力。 Swiss Advanced Vision首席执行官Max Boysset表示:“通过EDEN,我们从高视力性能方面巩固了现有的产品阵容,依据是我们收到患者热烈的反馈。而LUCIDIS的定位完全不同:它是突破性产品,向患者提供平价的延伸视力。LUCIDIS能够作为首款EDOF单焦点晶状体上市,我们感到很兴奋。我们的使命是向最大多数的患者提供瑞士生产的EDOF技术。SAV-IOL现在凭借LUCIDIS

革新的なスイス製の新しい白内障手術用EDOF IOLを2種投入

スイス・ヌーシャテル–(BUSINESS WIRE)–(ビジネスワイヤ) — Swiss Advanced Vision(SAV-IOL SA)は本日、白内障手術用の新しい眼内レンズ(IOL)として、LUCIDISおよびEDENの2種の市場投入を発表しました。両レンズとも、特許取得済みのInstant Focus EDOF技術を使用しています。LUCIDISはまったく新しい概念により、単焦点眼内レンズの市場に重要な2つの成果をたらします。すなわち単焦点レンズの焦点深度を拡大すると同時に、求めやすいEDOF IOLを初めて実現します。本製品は屈折関係の優れた設計のおかげで、近見/中間視力に対応できるよう拡大が可能です。同時にSAV-IOLは多焦点眼内レンズ市場でも、InFoレンズの成功を積み重ねています。便利なブリスター包装を施したEDENは、高級ハイブリッド眼内レンズのセグメントで基準となるもので、ハイパフォーマンスの連続的な視力を実現します。 Swiss Advanced VisionのMax Boysset最高経営責任者(CEO)は、次のように述べています。「当社はEDEN